Effect of Strength Training on Executive Functions in Elderly People With Mild Cognitive Impairment
NCT03946254, Not applicable, Unknown, University of Seville
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effect of Strength Training on Executive Functions in Elderly People With Mild Cognitive Impairment | ClinicalTrials.gov |
| NCT number | NCT03946254 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 40 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Seville | ClinicalTrials.gov |
| Conditions | Strength Training, Executive Function | ClinicalTrials.gov |
| Interventions | Effect of strength training on executive functions in elderly people with mild cognitive impairment. | ClinicalTrials.gov |
| First posted | 2019-05-10 | ClinicalTrials.gov |
| Last updated | 2019-05-10 | ClinicalTrials.gov |
Registered outcomes 26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Baseline of Inhibitory control | week 0 | To measure the inhibitory control, the "Stroop test" will be used. It is a short test and consists of 3 parts. In the first part they must read the greatest number of words in a sheet with a total of 100 words that appear in 5 columns. For 45 seconds they should read the largest number of words. At the end of the time the number will be written down of words read. Next, they should identify colors from a list of symbols without meaning, but colored in different colors. The subject will have to identify and name the greatest number of colors. Finally, the subject is given a list of words with the name of colors, but written with a different color from the one the word refers to.This test aims to assess the inhibitory control. | ClinicalTrials.gov |
| Primary | Mean Change from Baseline in Inhibitory control | week 21 | To measure the inhibitory control, the "Stroop test" will be used. It is a short test and consists of 3 parts. In the first part they must read the greatest number of words in a sheet with a total of 100 words that appear in 5 columns. For 45 seconds they should read the largest number of words. At the end of the time the number will be written down of words read. Next, they should identify colors from a list of symbols without meaning, but colored in different colors. The subject will have to identify and name the greatest number of colors. Finally, the subject is given a list of words with the name of colors, but written with a different color from the one the word refers to.This test aims to assess the inhibitory controlof words read. | ClinicalTrials.gov |
| Primary | Inhibitory control in the follow-up phase | week 33 | To measure the inhibitory control, the "Stroop test" will be used. It is a short test and consists of 3 parts. In the first part they must read the greatest number of words in a sheet with a total of 100 words that appear in 5 columns. For 45 seconds they should read the largest number of words. At the end of the time the number will be written down of words read. Next, they should identify colors from a list of symbols without meaning, but colored in different colors. The subject will have to identify and name the greatest number of colors. Finally, the subject is given a list of words with the name of colors, but written with a different color from the one the word refers to.This test aims to assess the inhibitory controlof words read. | ClinicalTrials.gov |
| Secondary | Baseline of general cognition | Week 0 | Global cognition is evaluated through the mini-mental test (Folstein, Folstein, \& McHugh, 1975). It is a brief and quick test to apply and is frequently used to diagnose the degree of cognitive decline. It should be noted how various variables such as the socio-educational level, and age among others, can affect the result. In addition, the mini-mental test is low cost and can be applied by any professional with a minimum of knowledge and training towards their development. The diagnostic values for mild cognitive impairment are between 24 and 28. | ClinicalTrials.gov |
| Secondary | Mean Change from Baseline in General cognition | week 21 | Global cognition is evaluated through the mini-mental test (Folstein, Folstein, \& McHugh, 1975). It is a brief and quick test to apply and is frequently used to diagnose the degree of cognitive decline. It should be noted how various variables such as the socio-educational level, and age among others, can affect the result. In addition, the mini-mental test is low cost and can be applied by any professional with a minimum of knowledge and training towards their development. The diagnostic values for mild cognitive impairment are between 24 and 28. | ClinicalTrials.gov |
| Secondary | General cognition in the follow-up phase | week 33 | Global cognition is evaluated through the mini-mental test (Folstein, Folstein, \& McHugh, 1975). It is a brief and quick test to apply and is frequently used to diagnose the degree of cognitive decline. It should be noted how various variables such as the socio-educational level, and age among others, can affect the result. In addition, the mini-mental test is low cost and can be applied by any professional with a minimum of knowledge and training towards their development. The diagnostic values for mild cognitive impairment are between 24 and 28. | ClinicalTrials.gov |
| Secondary | Baseline of physical condition | week 0 | Senior Fitness Test. This test battery allows us to evaluate the physical condition of elderly people safely. This battery can develop in ages from 60 to 94 years, encompassing various levels of physical and functional capacity (Rikli \& Jones, 1999).Due to its easy application, no specific material is required for its development, so it can be developed outside the laboratory. This test battery consists of 7 tests: The tests described here are quantified by the distance achieved. Test of flexibility of the lower extremities, Put your hands behind your back, Get up and walk and sit down again. In all the tests, the distance or number of repetitions made will be noted to later make comparisons with reference tables already established according to the ages. | ClinicalTrials.gov |
| Secondary | Mean Change from Baseline in Physical condition | week 21 | Senior Fitness Test. This test battery allows us to evaluate the physical condition of elderly people safely. This battery can develop in ages from 60 to 94 years, encompassing various levels of physical and functional capacity (Rikli \& Jones, 1999).Due to its easy application, no specific material is required for its development, so it can be developed outside the laboratory. This test battery consists of 7 tests: The tests described here are quantified by the distance achieved. Test of flexibility of the lower extremities, Put your hands behind your back, Get up and walk and sit down again. In all the tests, the distance or number of repetitions made will be noted to later make comparisons with reference tables already established according to the ages. | ClinicalTrials.gov |
| Secondary | Physical condition in the follow-up phase | week 33 | Senior Fitness Test. This test battery allows us to evaluate the physical condition of elderly people safely. This battery can develop in ages from 60 to 94 years, encompassing various levels of physical and functional capacity (Rikli \& Jones, 1999).Due to its easy application, no specific material is required for its development, so it can be developed outside the laboratory. This test battery consists of 7 tests: The tests described here are quantified by the distance achieved. Test of flexibility of the lower extremities, Put your hands behind your back, Get up and walk and sit down again. In all the tests, the distance or number of repetitions made will be noted to later make comparisons with reference tables already established according to the ages. | ClinicalTrials.gov |
| Secondary | Baseline of physical condition variante | week 0 | Senior Fitness Test. This test battery allows us to evaluate the physical condition of elderly people safely. This battery can develop in ages from 60 to 94 years, encompassing various levels of physical and functional capacity (Rikli \& Jones, 1999).Due to its easy application, no specific material is required for its development, so it can be developed outside the laboratory. This test battery consists of 7 tests. The tests described here are quantified by the maximum number of repetitions performed. Sit and get up from a chair for 30 seconds, push-ups for 30 seconds, In all the tests, the distance or number of repetitions made will be noted to later make comparisons with reference tables already established according to the ages. | ClinicalTrials.gov |
| Secondary | Mean Change from Baseline in Physical condition variante | week 21 | Senior Fitness Test. This test battery allows us to evaluate the physical condition of elderly people safely. This battery can develop in ages from 60 to 94 years, encompassing various levels of physical and functional capacity (Rikli \& Jones, 1999).Due to its easy application, no specific material is required for its development, so it can be developed outside the laboratory. This test battery consists of 7 tests. The tests described here are quantified by the maximum number of repetitions performed. Sit and get up from a chair for 30 seconds, push-ups for 30 seconds, In all the tests, the distance or number of repetitions made will be noted to later make comparisons with reference tables already established according to the ages. | ClinicalTrials.gov |
| Secondary | Physical condition variante in the follow-up phase | week 33 | Senior Fitness Test. This test battery allows us to evaluate the physical condition of elderly people safely. This battery can develop in ages from 60 to 94 years, encompassing various levels of physical and functional capacity (Rikli \& Jones, 1999).Due to its easy application, no specific material is required for its development, so it can be developed outside the laboratory. This test battery consists of 7 tests. The tests described here are quantified by the maximum number of repetitions performed. Sit and get up from a chair for 30 seconds, push-ups for 30 seconds, In all the tests, the distance or number of repetitions made will be noted to later make comparisons with reference tables already established according to the ages. | ClinicalTrials.gov |
| Secondary | Baseline of blood test | week 0 | Only 15 ml of blood will be extracted from the antecubital vein to measure the concentrations of different biochemical parameters, such as the BDFN and IGF-1. To avoid interferences in the blood analysis, it is necessary that the patient goes on an empty stomach. It is also necessary that during the previous day the participant fulfills a normal sleep monitoring cycle and that he does not eat chocolate, cocoa, tea, coffee or any other stimulant. | ClinicalTrials.gov |
| Secondary | Mean Change from Baseline in Blood test | week 21 | Only 15 ml of blood will be extracted from the antecubital vein to measure the concentrations of different biochemical parameters, such as the BDFN and IGF-1. To avoid interferences in the blood analysis, it is necessary that the patient goes on an empty stomach. It is also necessary that during the previous day the participant fulfills a normal sleep monitoring cycle and that he does not eat chocolate, cocoa, tea, coffee or any other stimulant. | ClinicalTrials.gov |
| Secondary | Baseline of strength | week 0 | The point of maximum power is an elaborate and accurate assessment of muscle strength and is often evaluated at a speed of 60º per second. Therefore, the Biodex 4 system will be used to assess the capacity to generate the power peak of each subjectby knee extension. | ClinicalTrials.gov |
| Secondary | Mean Change from Baseline in Strength | week 21 | The point of maximum power is an elaborate and accurate assessment of muscle strength and is often evaluated at a speed of 60º per second. Therefore, the Biodex 4 system will be used to assess the capacity to generate the power peak of each subjectby knee extension. | ClinicalTrials.gov |
| Secondary | Strength in the follow-up phase | week 33 | The point of maximum power is an elaborate and accurate assessment of muscle strength and is often evaluated at a speed of 60º per second. Therefore, the Biodex 4 system will be used to assess the capacity to generate the power peak of each subjectby knee extension. | ClinicalTrials.gov |
| Secondary | Baseline of cognitive flexibility | week 0 | To evaluate the cognitive flexibility, will be used the WISCONSIN TEST. This test consists of two sets of 64 cards. The letters present various combinations according to 4 geometric shapes, 4 colors and 4 quantities. | ClinicalTrials.gov |
| Secondary | Mean Change from Baseline in cognitive flexibility | week 21 | To evaluate the cognitive flexibility, will be used the WISCONSIN TEST. This test consists of two sets of 64 cards. The letters present various combinations according to 4 geometric shapes, 4 colors and 4 quantities. | ClinicalTrials.gov |
| Secondary | cognitive flexibility in the follow-up phase | week 33 | To evaluate the cognitive flexibility, will be used the WISCONSIN TEST. This test consists of two sets of 64 cards. The letters present various combinations according to 4 geometric shapes, 4 colors and 4 quantities. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)